<DOC>
	<DOCNO>NCT02562664</DOCNO>
	<brief_summary>Polycystic ovary syndrome ( PCOS ) common Female endocrine disorder , prevalence range 6 % to10 % base National Institutes Health ( NIH ) criterion broad Rotterdam criterion apply reach high 15 % . Typically , PCOS identify early adolescence . Insulin resistance common find obese woman PCOS . It prevalent severe PCOS phenotype involve hyperandrogenism chronic anovulation . Women PCOS regular cycle metabolically less abnormal . Acanthosis nigricans ( AN ) dermatosis characterize velvety , papillomatous , brownish-black , hyperkeratotic plaque , typically intertriginous surface neck . Although AN associated malignancy , recognition common connection obesity insulin resistance allow diagnosis related disorder include type 2 diabetes , metabolic syndrome , polycystic ovary syndrome . Significant improvement ovulation pregnancy rate result clomiphene treatment metformin woman clomiphene-resistant PCOS report popular randomize , double-blind , placebo-controlled trial . The first pharmacological approach induction ovulation woman PCOS clomiphene citrate</brief_summary>
	<brief_title>Metformin Improves Clinical Pregnancy Rate Polycystic Ovarian Syndrome Patients</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Polycystic Ovary Syndrome</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Clomiphene</mesh_term>
	<mesh_term>Enclomiphene</mesh_term>
	<mesh_term>Zuclomiphene</mesh_term>
	<criteria>All patient PCOS fulfil least 2 three criterion Rotterdam consensus 2003 liver disease heart respiratory failure alcohol abuse kidney disease</criteria>
	<gender>Female</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>January 2014</verification_date>
</DOC>